CN103142642B - Calcitriol and calcium carbonate suspension granule and preparation method thereof - Google Patents

Calcitriol and calcium carbonate suspension granule and preparation method thereof Download PDF

Info

Publication number
CN103142642B
CN103142642B CN201310091552.3A CN201310091552A CN103142642B CN 103142642 B CN103142642 B CN 103142642B CN 201310091552 A CN201310091552 A CN 201310091552A CN 103142642 B CN103142642 B CN 103142642B
Authority
CN
China
Prior art keywords
calcitriol
calcium carbonate
suspension grain
mix suspension
mix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310091552.3A
Other languages
Chinese (zh)
Other versions
CN103142642A (en
Inventor
王明刚
陈阳生
任莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CP Pharmaceutical Qingdao Co Ltd
Original Assignee
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Chia Tai Haier Pharmaceutical Co Ltd filed Critical Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Priority to CN201310091552.3A priority Critical patent/CN103142642B/en
Publication of CN103142642A publication Critical patent/CN103142642A/en
Application granted granted Critical
Publication of CN103142642B publication Critical patent/CN103142642B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a calcitriol and calcium carbonate suspension granule and a preparation method thereof. The suspension granule is prepared from the following ingredients in percentage by weight: 0.0005% of calcitriol, 5-10% of calcium carbonate, 2.0-4.0% of meglumine, 1.2-1.8% of polyethylene glycol 400, 12-18% of polyethylene glycol 6000, 45-75% of filler, 5.0-10.0% of disintegrant and an appropriate amount of binder. According to the suspension granule, the content of calcitriol is remarkably increased, so that the drug dosage is reduced; and the stability of calcitriol to light and air is improved, and the bioavailability of calcitriol is also remarkably improved.

Description

Mix suspension grain of calcitriol and calcium carbonate and preparation method thereof
Technical field
The present invention relates to pharmaceutical technology field, be specifically related to mix suspension grain of a kind of calcitriol and calcium carbonate and preparation method thereof.
Background technology
Calcitriol (Calcitriol) is white crystalline powder, to light and air-sensitive.Be slightly soluble in methanol, ethanol, ethyl acetate.Tm is 111-115 ℃.It is one of most important metabolic activity product of vitamin D3 in human body, has the intestinal absorption of impelling calcium and regulates in sclerotin the effects such as inorganic salt transhipment; Be mainly used in osteoporosis; The renal osteodystrophy of Patients with Chronic Renal Failure, particularly needs the patient of chronic hemodialysis; After operation, spontaneity and false parathyroid gland machine go down; Vitamin D3 dependency rickets and hypophosphatemia vitamin D resistance rickets; The dermatosiss such as psoriasis; And other vitamin D deficiencies.The oral absorption of calcitriol is fast, within 3~6 hours, reaches peak, t1/2 approximately 3~6 hours, and after 7 hours, urinating calcium concentration increases, the sustainable pharmacologically active of single oral dose 3~5 days.Strontium Ranelate, as a kind of new compound, has anti-bone resorption and promotes bone formation dual function, can be used in treatment osteoporosis.The osteoporosis that calcitriol and Strontium Ranelate administering drug combinations be can be used for treating to various former or secondary.
Calcium carbonate is the best of being widely used raw material of replenishing the calcium, its calcium content is high, cheap, good absorbing in body, but comparatively common with chewable tablet on the market, although there is the advantage of its preparation itself, also obviously there is defect in some place, such as the poor children taking of masticatory ability, child is in eugonic period, and current domestic child's great majority all need to replenish the calcium, and chewable tablet is obviously not suitable for children taking.
When calcitriol and calcium carbonate are made to compositions and share, because calcitriol is to light and air-sensitive, said composition exists the content of effective ingredient calcitriol extremely low, the problem that bioavailability is low.
Summary of the invention
Research worker is surprisingly found, while preparing the mix suspension grain of calcitriol and calcium carbonate, the meglumine adding in right amount, PEG400 and polyethylene glycol 6000, can significantly improve content, stability and the bioavailability of calcitriol in preparation, thereby can reduce the consumption of calcium carbonate, so there is unforeseeable technique effect, significant for the clinical use of medicine.
The invention provides a kind of active component content is high, medicine stability good, bioavailability is high calcitriol and the mix suspension grain of calcium carbonate.This mix suspension grain is made by the component of following percentage by weight:
Calcitriol 0.0005%
Calcium carbonate 5-10%
Meglumine 2.0-4.0%
PEG400 1.2-1.8%
Polyethylene glycol 6000 12-18%
Filler 45-75%
Disintegrating agent 5.0-10.0%
Binding agent is appropriate.
Its optimizing prescriptions is:
Calcitriol 0.0005%
Calcium carbonate 8.0%
Meglumine 3.0%
PEG400 1.5%
Polyethylene glycol 6000 15%
Filler 60%
Disintegrating agent 8.0%
Binding agent is appropriate.
Further, above-mentioned filler is selected from one or more in starch, lactose, dextrin, amylum pregelatinisatum and Icing Sugar.
Further, above-mentioned disintegrating agent is selected from one or more in carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose and sodium alginate.
Further, above-mentioned binding agent is selected from one or more in starch, pregelatinized Starch, hyprolose, hypromellose and polyvidone.
The preparation method of this mix suspension grain is:
1) take the supplementary material of recipe quantity, cross respectively 80-120 mesh sieve standby;
2) binding agent of getting after sieving adds distilled water, makes binder solution;
3) by the calcitriol after sieving, calcium carbonate, meglumine, PEG400, polyethylene glycol 6000, filler and disintegrating agent by equivalent incremental method mix homogeneously, add above-mentioned binder solution to make soft material;
4), after granulating with 40 mesh sieves, dry 30-60min at 50-70 ℃, crosses 20 mesh sieve granulate; After No. 4 sieve sieves, remove fine powder, subpackage, sealing, packing and get final product.
The preparation method of this mix suspension grain is more preferably:
1) take the supplementary material of recipe quantity, cross respectively 100 mesh sieves standby;
2) binding agent of getting after sieving adds distilled water, makes binder solution;
3) by the calcitriol after sieving, calcium carbonate, meglumine, PEG400, polyethylene glycol 6000, filler and disintegrating agent by equivalent incremental method mix homogeneously, add above-mentioned binder solution to make soft material;
4) after granulating with 40 mesh sieves, dry 45min at 60 ℃, crosses 20 mesh sieve granulate, after No. 4 sieve sieves, removes fine powder, subpackage, sealing, packing and get final product.
The invention has the beneficial effects as follows:
1. in said preparation, the content of calcitriol significantly increases, and has reduced the dose of medicine;
2. improved the stability of calcitriol to light, air having added of meglumine, PEG400 and polyethylene glycol 6000, its bioavailability is also significantly improved, thereby has reduced the consumption of calcium carbonate in compositions.
The specific embodiment
Below in conjunction with concrete embodiment, technical scheme of the present invention is further described.
The mix suspension grain of embodiment 1 calcitriol and calcium carbonate
Prescription is:
Calcitriol 1.5mg
Calcium carbonate 15g
Meglumine 6.0g
PEG400 3.6g
Polyethylene glycol 6000 36g
Starch 210g
Carboxymethyl starch sodium 15g
Pregelatinized Starch is appropriate.
Preparation method is:
1) take the supplementary material of recipe quantity, cross respectively 80 mesh sieves standby;
2) pregelatinized Starch of getting after sieving adds distilled water, makes binder solution;
3) by the calcitriol after sieving, calcium carbonate, meglumine, PEG400, polyethylene glycol 6000, starch and carboxymethyl starch sodium by equivalent incremental method mix homogeneously, add above-mentioned binder solution to make soft material;
4) after granulating with 40 mesh sieves, dry 30min at 50 ℃, crosses 20 mesh sieve granulate, after No. 4 sieve sieves, removes fine powder, subpackage, sealing, packing and get final product.
The mix suspension grain of embodiment 2 calcitriols and calcium carbonate
Prescription is:
Calcitriol 1.5mg
Calcium carbonate 30g
Meglumine 12g
PEG400 5.4g
Polyethylene glycol 6000 54g
Lactose 150g
Low-substituted hydroxypropyl cellulose 30g
Hyprolose is appropriate.
Preparation method is:
1) take the supplementary material of recipe quantity, cross respectively 120 mesh sieves standby;
2) hyprolose of getting after sieving adds distilled water, makes binder solution;
3) by the calcitriol after sieving, calcium carbonate, meglumine, PEG400, polyethylene glycol 6000, lactose and low-substituted hydroxypropyl cellulose by equivalent incremental method mix homogeneously, add above-mentioned binder solution to make soft material;
4) after granulating with 40 mesh sieves, dry 60min at 70 ℃, crosses 20 mesh sieve granulate, after No. 4 sieve sieves, removes fine powder, subpackage, sealing, packing and get final product.
The mix suspension grain of embodiment 3 calcitriols and calcium carbonate
Prescription is:
Calcitriol 1.5mg
Calcium carbonate 24g
Meglumine 9.0g
PEG400 4.5g
Polyethylene glycol 6000 45g
Dextrin 180g
Microcrystalline Cellulose 24.0g
Polyvidone is appropriate.
Preparation method is:
1) take the supplementary material of recipe quantity, cross respectively 100 mesh sieves standby;
2) polyvidone of getting after sieving adds distilled water, makes binder solution;
3) by the calcitriol after sieving, calcium carbonate, meglumine, PEG400, polyethylene glycol 6000, dextrin and microcrystalline Cellulose by equivalent incremental method mix homogeneously, add above-mentioned binder solution to make soft material;
4) after granulating with 40 mesh sieves, dry 45min at 60 ℃, crosses 20 mesh sieve granulate, after No. 4 sieve sieves, removes fine powder, subpackage, sealing, packing and get final product.
The mix suspension grain of comparing embodiment 1 calcitriol and calcium carbonate
Calcitriol 1.5mg
Calcium carbonate 24g
PEG400 4.5g
Polyethylene glycol 6000 45g
Dextrin 180g
Microcrystalline Cellulose 24.0g
Polyvidone is appropriate.
Preparation method is same embodiment 3:
The mix suspension grain of comparing embodiment 2 calcitriols and calcium carbonate
Calcitriol 1.5mg
Calcium carbonate 24g
Meglumine 9.0g
Polyethylene glycol 6000 45g
Dextrin 180g
Microcrystalline Cellulose 24.0g
Polyvidone is appropriate.
Preparation method is with embodiment 3.
The mix suspension grain of comparing embodiment 3 calcitriols and calcium carbonate
Calcitriol 1.5mg
Calcium carbonate 24g
Meglumine 9.0g
PEG400 4.5g
Dextrin 180g
Microcrystalline Cellulose 24.0g
Polyvidone is appropriate.
Preparation method is with embodiment 3.
Embodiment 4 stability experiments and result
1. accelerated stability test
Intensity of illumination 4500lx, adopted HPLC method to carry out assay in the 0th, 5 and 10 days after timing sampling.
The condition of HPLC is: chromatographic column: ODS-C18 post, take octadecylsilane chemically bonded silica as filler; Mobile phase: acetonitrile-water (75:25); Detect wavelength: 265nm; Flow velocity: 1.0mL/min; Sample size: 50 μ L.Theoretical cam curve is pressed the calculating of calcitriol peak should be not low by 5000, and calcitriol peak and the peak-to-peak separating degree of trans calcitriol should be greater than 1.0.Adopt external standard method to calculate content.Assay result (percentage ratio of the amount of recording and labelled amount) sees the following form 1.Result shows that the stability of active component calcitriol in the mix suspension grain of calcitriol of the present invention and calcium carbonate is obviously better than comparative example.
Table 1 accelerated stability test assay result (%)
2. long-term stable experiment
25 ℃ of temperature, relative humidity are placed 36 months for 60% time, respectively at 0,3,6,12,24 and 36 months time sampling adopt HPLC method to carry out assay.The same accelerated stability test of condition of HPLC.Adopt external standard method to calculate content.Assay result (percentage ratio of the amount of recording and labelled amount) sees the following form 2.Result shows that the stability of active component calcitriol in the mix suspension grain of calcitriol of the present invention and calcium carbonate is obviously better than comparative example.
Table 2 long-term stable experiment assay result (%)
The comparative test of embodiment 5 bioavailability
4 beasle dogs (being male) are carried out to oral administration, they are fed respectively with the embodiment of the present invention 3, comparative example 1, comparative example 2, comparative example 3 calcitriol and the mix suspension grain of calcium carbonate (25 ℃ of temperature, relative humidity are placed 12 months for 60% time), dosage is 5.0 μ g/ only (in calcitriol), and be 7 days the interval time of each administration.Give after medicine, blood sample collection under different time, and carry out the maximum haemoconcentration (C of calcitriol max) and bioavailability (AUC 0 → 48) calculating.Acquisition time is 0h, 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 24h, 32h, 48h.
Following table 3 provides the average result that 4 beasle dogs is given to the embodiment of the present invention 3, comparative example 1, comparative example 2, comparative example's 3 calcitriol and the mix suspension grain gained of calcium carbonate.As seen from table, the maximum haemoconcentration of the calcitriol of the mix suspension grain of calcitriol of the present invention and calcium carbonate (embodiment 3) and bioavailability are apparently higher than comparative example.
The comparison of table 3 bioavailability (5.0 μ g, n=3)
Should be noted that; the foregoing is only preferred embodiment of the present invention; be not limited to scope of the present invention, every any modification of having done within the spirit and principles in the present invention, the replacement being equal to and improvement etc., within all should being included in protection scope of the present invention.

Claims (7)

1. a mix suspension grain for calcitriol and calcium carbonate, is characterized in that, by the component of following percentage by weight, is made:
2. the mix suspension grain of calcitriol according to claim 1 and calcium carbonate, is characterized in that, by the component of following percentage by weight, is made:
3. the mix suspension grain of calcitriol according to claim 1 and 2 and calcium carbonate, is characterized in that, described filler is selected from one or more in starch, lactose, dextrin and Icing Sugar.
4. the mix suspension grain of calcitriol according to claim 1 and 2 and calcium carbonate, it is characterized in that, described disintegrating agent is selected from one or more in carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose and sodium alginate.
5. the mix suspension grain of calcitriol according to claim 1 and 2 and calcium carbonate, is characterized in that, described binding agent is selected from one or more in starch, hyprolose, hypromellose and polyvidone.
6. the preparation method of the mix suspension grain of the calcitriol described in claim 1-5 any one and calcium carbonate, is characterized in that, the method comprises the steps:
1) take the supplementary material of recipe quantity, cross respectively 80-120 mesh sieve standby;
2) binding agent of getting after sieving adds distilled water, makes binder solution;
3) by the calcitriol after sieving, calcium carbonate, meglumine, PEG400, polyethylene glycol 6000, filler and disintegrating agent by equivalent incremental method mix homogeneously, add above-mentioned binder solution to make soft material;
4), after granulating with 40 mesh sieves, dry 30-60min at 50-70 ℃, crosses 20 mesh sieve granulate; After No. 4 sieve sieves, remove fine powder, subpackage, sealing, packing and get final product.
7. the preparation method of the mix suspension grain of calcitriol claimed in claim 6 and calcium carbonate, is characterized in that, the method comprises the steps:
1) take the supplementary material of recipe quantity, cross respectively 100 mesh sieves standby;
2) binding agent of getting after sieving adds distilled water, makes binder solution;
3) by the calcitriol after sieving, calcium carbonate, meglumine, PEG400, polyethylene glycol 6000, filler and disintegrating agent by equivalent incremental method mix homogeneously, add above-mentioned binder solution to make soft material;
4) after granulating with 40 mesh sieves, dry 45min at 60 ℃, crosses 20 mesh sieve granulate, after No. 4 sieve sieves, removes fine powder, subpackage, sealing, packing and get final product.
CN201310091552.3A 2013-03-21 2013-03-21 Calcitriol and calcium carbonate suspension granule and preparation method thereof Active CN103142642B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310091552.3A CN103142642B (en) 2013-03-21 2013-03-21 Calcitriol and calcium carbonate suspension granule and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310091552.3A CN103142642B (en) 2013-03-21 2013-03-21 Calcitriol and calcium carbonate suspension granule and preparation method thereof

Publications (2)

Publication Number Publication Date
CN103142642A CN103142642A (en) 2013-06-12
CN103142642B true CN103142642B (en) 2014-07-23

Family

ID=48541151

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310091552.3A Active CN103142642B (en) 2013-03-21 2013-03-21 Calcitriol and calcium carbonate suspension granule and preparation method thereof

Country Status (1)

Country Link
CN (1) CN103142642B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101554372B (en) * 2009-05-20 2011-07-20 青岛正大海尔制药有限公司 Calcitriol dripping pill and preparation method thereof
CN102973528B (en) * 2012-11-19 2014-07-09 中山大学 Calcitriol solid lipidic dispersion and preparation method thereof

Also Published As

Publication number Publication date
CN103142642A (en) 2013-06-12

Similar Documents

Publication Publication Date Title
CN103142524B (en) Calcitriol tablet and preparation method thereof
CN103142470B (en) Calcitriol injection and preparation method thereof
CN105193707A (en) Ambroxol hydrochloride oral solution and preparation method thereof
CN103142471B (en) Calcitriol solution and preparation method thereof
CN103142623B (en) Calcitriol and strontium ranelate suspension granule and preparation method thereof
CN103142501B (en) Calcitriol pellet and preparation method thereof
CN103142478B (en) Calcitriol emulsion and preparation method thereof
CN103142554B (en) Calcitriol controlled-release capsule and preparation method thereof
CN103142534B (en) Calcitriol controlled-release tablet and preparation method thereof
CN103142642B (en) Calcitriol and calcium carbonate suspension granule and preparation method thereof
CN103142546B (en) Calcitriol capsule and preparation method thereof
CN103142496B (en) Calcitriol controlled-release granule and preparation method thereof
CN104739793B (en) A kind of Alfacalcidol piece and preparation method thereof
CN103142644B (en) Calcitriol and sodium fluoride suspension granule and preparation method thereof
CN103142536B (en) Calcitriol enteric tablet and preparation method thereof
CN103142547B (en) Calcitriol enteric capsule and preparation method thereof
CN103142495B (en) Calcitriol suspension granule and preparation method thereof
CN106265556A (en) A kind of doxercalciferol sheet and preparation method thereof
CN103142486B (en) Calcitriol powder and preparation method thereof
CN103142498B (en) Calcitriol enteric granule and preparation method thereof
CN103142467B (en) Calcitriol ointment and preparation method thereof
CN103142476B (en) Calcitriol suspension and preparation method thereof
CN102068431B (en) Carbazole sulfamide-derived anti-tumor medicine tablets and preparation method thereof
CN103142466B (en) Calcitriol gel and preparation method thereof
CN103330944A (en) Bicyclol oral solid pharmaceutical composition, and preparation and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 266103 Qingdao economic and Technological Development Zone, unity Road, No. 3601, Shandong

Applicant after: Qingdao Zhengda Haier Pharmaceutical Co., Ltd.

Address before: 266103 Haier Road, Shandong, Qingdao, No. 1

Applicant before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong

Patentee after: Zhengda Pharmaceutical (Qingdao) Co., Ltd.

Address before: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong

Patentee before: Qingdao Zhengda Haier Pharmaceutical Co., Ltd.